A5029834585- Immunotherapy and Immune Responses
- Glycosylation and Glycoproteins Research
- Prostate Cancer Treatment and Research
- Peptidase Inhibition and Analysis
- Ubiquitin and proteasome pathways
- Cancer-related gene regulation
- RNA Research and Splicing
- Mass Spectrometry Techniques and Applications
Newcastle University
2023-2024
Abstract Immune checkpoint blockade has yet to produce robust anti-cancer responses for prostate cancer. Sialyltransferases have been shown across several solid tumours, including breast, melanoma, colorectal and promote immune suppression by synthesising sialoglycans, which act as ligands Siglec receptors. We report that ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) levels negatively correlate with androgen signalling in tumours. demonstrate ST3Gal1 plays an important role...
Aberrant androgen receptor (AR) signaling drives prostate cancer (PC), and it is a key therapeutic target. Although initially effective, the generation of alternatively spliced AR variants (AR-Vs) compromises efficacy treatments. In contrast to full-length (AR-FL), AR-Vs constitutively activate androgenic are refractory current repertoire AR-targeting therapies, which together drive disease progression. There an unmet clinical need, therefore, develop more durable PC therapies that can...
Abstract Resistance to androgen receptor (AR)-targeted therapies represent a major challenge in prostate cancer (PC). A key mechanism of treatment resistance patients who progress castrate-resistant PC (CRPC) is the generation alternatively spliced variants (AR-Vs). Unlike full-length AR (FL-AR) isoforms, AR-Vs are constitutively active and refractory current receptor-targeting agents hence drive tumour progression. Identifying regulators AR-V synthesis may therefore provide new therapeutic...
Abstract Immune checkpoint blockade trials have yet to produce a robust anti-cancer response in prostate cancer patients as monotherapy due the immunosuppressed tumour immune microenvironment. ST3Gal1 and other sialyltransferases are implicated suppression by synthesizing sialoglycans, which act ligands for Siglec receptors. These checkpoints important response. However, it’s unclear how synthesis of is regulated, little known about role sialoglycan-Siglec-axis cancer’s evasion anti-tumour...